IMODE

You are here

Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications

Priority Axis

Technological and Social Innovation

Specific objective

Technological Innovation

France

University Lille 1 - Unité Matériaux et Transformations

Lead partner

address

Avenue Paul Langevin
Villeneuve d'Ascq
France

Contact

Project budget

5 960 060

ERDF amount

3 576 036

ERDF rate

60%
22.3%

Common challenge

The IMODE project is motivated by an unmet need for developing solutions to address societal challenges for improved healthcare, novel medicines while maintaining low medical costs. This will be achieved with the collaboration of academic research groups and SMEs through a transdisciplinary applied research programme in materials science, pharmacy, biology and medicine. The project will strengthen innovation in the 2 Seas Area in order to obtain a strategic advantage for novel pharmaceutical and medical applications bridging the current gap between academia and the private sector.

Partners

England

University College London, UCL School of Pharmacy

France

Université Lille 2 Droit et Santé

Belgium/Flanders

Universiteit Gent Laboratory of Pharmaceutical Technology

England

University of East Anglia

France

ImaBiotech

England

University of Greenwich

France

G.I.E Eurasanté

England

Ashford and St Peter's Hospital's NHS Foundation Trust

England

Cubic Pharmaceuticals Limited

France

Roquette Frères

Observers

France

Fondation DigestScience

England

The Chancellor, Masters and Scholars of the University of Cambridge

France

NOVITOM

England

Cyversa

England

Linkam Scientific Instruments Ltd

England

Different Strokes

France

Fédération des biomatériaux et dispositifs médicaux fonctionnalisés du Nord-Pas de Calais